Jamp-Tenofovir · DIN 02479087 · 300mg · tablet
Limited Use — Reason for Use code 517, 518, 519, 520, 521, 522 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 517, 518, 519, 520, 521, 522 required
Write on scriptLU code 517, 518, 519, 520, 521, 522 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 517, 518, 519, 520, 521, 522
Reason for Use code 517
Confirmed chronic Hepatitis B infection in persons with
- HBV DNA greater than or equal to 1000 IU/mL
AND
- ALT levels greater than ULN
OR
- Evidence of fibrosis
OR
- Documented evidence of cirrhosis
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 518
For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, entecavir, adefovir or telbivudine.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 519
Patient is pregnant (2nd trimester or later) with HBV DNA greater than 1,000,000 IU/mL.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 520
Patients with chronic Hepatitis B infection currently receiving treatment with tenofovir and requires treatment continuation.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 521
Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 522
For HIV/AIDS.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Tenofovir · DIN 02479087
Manufacturer: Jamp Pharma Corporation; listing date 2019-02-28
Health Canada: Marketed since 2018-10-24 · brand JAMP-TENOFOVIR · ATC J05AF07 TENOFOVIR DISOPROXIL · form Tablet · route Oral · ingredients TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Tenofovir: Formulary list price $4.8884/unit (unit not stated in source; not the patient's cost)
Ministry pays: $4.8884 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96979 · Verify on the e-Formulary ↗ (DIN 02479087)
Source record
DIN 02479087: Jamp-Tenofovir
Raw flags: sec12=Y, sec3=Y
Item: 081800083; group id 113; item number 0195; lccId 00297; manufacturer id JPC
Source form: Tab; strength: 300mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $4.8884; ministry $4.8884
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479087
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96979
Interchangeable products
Apo-Tenofovir · DIN 02451980 · $4.8884
Auro-Tenofovir · DIN 02460173 · $4.8884
Mint-Tenofovir · DIN 02512939 · $4.8884
Mylan-Tenofovir Disoproxil · DIN 02452634 · $4.8884
Nat-Tenofovir · DIN 02472511 · $4.8884
PMS-Tenofovir · DIN 02453940 · $4.8884
Tenofovir · DIN 02512327 · $4.8884
Tenofovir · DIN 02523922 · $4.8884
Teva-Tenofovir · DIN 02403889 · $4.8884
Viread · DIN 02247128 · $4.8884
Shortage status: not checked (no credentials)